Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 8, 2020
(Exact name of registrant as specified in its charter)
Delaware 001-37798 26-1622110
(State or other jurisdiction
of incorporation)
File Number)
 (IRS Employer
Identification No.)

65 Grove Street, Watertown, MA 02472
(Address of principal executive offices)(Zip Code)
(617) 923-1400
Registrant’s telephone number, including area code
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock (Par Value $0.0001)SELBThe Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01 Other Items
On October 8, 2020, Selecta Biosciences, Inc. (the “Company”) and IGAN Biosciences, Inc., a Delaware corporation (“IGAN”) entered into an Option and License Agreement (the “IGAN Agreement”). Pursuant to the IGAN Agreement, IGAN will grant the Company an exclusive license to research, evaluate, and conduct pre-clinical development activities on IGAN’s proprietary IgA Proteases. The company will have an option term of 24 months (the “Option Term”), during which it can elect to obtain an exclusive license to further develop and commercialize the product to treat all IgA Protease-mediated diseases, including IgA nephropathy, Linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura (also known as IgA vasculitis).
The Company will pay IGAN a one-time up-front payment of USD $500,000 within ten (10) business days of signing the IGAN Agreement, and the Company will owe additional payments to IGAN upon opting-in to an exclusive license agreement, as well as upon the achievement of certain development and sales milestones.
During the Option Term, the Company may terminate the IGAN Agreement immediately for any reason upon written notice to IGAN. If the Company opts-in to an exclusive license agreement, the Company may terminate the IGAN Agreement upon 120 days’ written notice.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 8, 2020By:/s/ Carsten Brunn, Ph.D.
  Carsten Brunn, Ph.D.
  President and Chief Executive Officer